CL
ITCI

CSS LLC’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

CSS LLC’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,000
Closed -$1.58M – 1206
2025
Q1 		$1.58M Buy
+12,000
New +$1.5M 0.09% 179
2023
Q1 		– Sell
-43,200
Closed -$2.29M – 934
2022
Q4 		$2.29M Buy
43,200
+31,300
+263% +$1.57M 0.13% 157
2022
Q3 		$554K Sell
11,900
-45,600
-79% -$2.38M 0.03% 489
2022
Q2 		$3.28M Buy
57,500
+6,400
+13% +$363K 0.13% 178
2022
Q1 		$3.13M Buy
51,100
+8,100
+19% +$421K 0.11% 176
2021
Q4 		$2.25M Buy
+43,000
New +$1.81M 0.08% 226
2021
Q2 		– Sell
-6,000
Closed -$204K – 1193
2021
Q1 		$204K Buy
+6,000
New +$208K 0.01% 769
2020
Q4 		– Sell
-14,200
Closed -$365K – 963
2020
Q3 		$365K Sell
14,200
-11,000
-44% -$251K 0.02% 472
2020
Q2 		$647K Buy
+25,200
New +$510K 0.04% 340
2020
Q1 		– Sell
-27,400
Closed -$941K – 784
2019
Q4 		$941K Buy
+27,400
New +$329K 0.05% 260

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

CSS LLC's ITCI Position: Q2 2025 in Review

CSS LLC sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 28,904 shares — an estimated $3.81M sold.

CSS LLC first reported a position in ITCI in Q4 2019 and held it in 14 quarters. The position peaked at $3.81M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • CSS LLC reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • CSS LLC sold 28,904 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.81M.
  • CSS LLC first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 14 quarters.
  • CSS LLC's Intra-Cellular Therapies Inc. position peaked at $3.81M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on CSS LLC's 13F filing for Q2 2025, filed 14 Aug 2025.